1st May 2025
LATS
Cambridge
MagnetOs™ Bone Graft: Advancing Orthobiological Innovation
Features
- Predictable fusion outcomes for reliable surgical results.†1-6
- Advanced NeedleGrip™ technology for optimal bone growth.†1-6
- Safe, and free from animal- or human-derived materials.7
At LEDA Orthopaedics, we are committed to delivering transformative solutions for orthopaedic & trauma procedures. MagnetOs is a bone graft like no other, powered by groundbreaking NeedleGrip™ surface technology, offering surgeons a reliable and predictable option for bone fusion in trauma & extremities surgery. 1,2,6,8
Key Features
- NeedleGrip™ Technology: Promotes bone growth by engaging pro-healing immune cells (M2 macrophages) and stimulating stem cell differentiation into osteoblasts. 1-3,9-11
- Versatility: Suitable for use in trauma, extremities (foot & ankle, upper limb), hip & knee and pelvic reconstruction, adapting to diverse surgical applications. 7
- Ethical and Safe: Free from animal and human-derived materials, addressing ethical concerns and ensuring patient confidence. 7
- Optimised Handling: Easy to shape, resistant to irrigation and migration, and simple to store and apply. 7
- Proven Performance: 400 patients evaluated in Level I, randomized controlled clinical trials and >20 well-controlled Level I-IV clinical trials initiated, including 6 that are complete.
Function of MagnetOs Bone Graft
MagnetOs is a revolutionary bone graft solution designed to support bone growth even in the most challenging environments. By leveraging innovative NeedleGrip™ surface technology, MagnetOs redefines trauma & orthopaedic procedures and delivers exceptional results without the need for added cells or growth factors. 1-3,6,7
Mechanism of Action
Understanding how MagnetOs works is key to appreciating its groundbreaking impact on orthopaedic care. The NeedleGrip™ surface technology drives a multi-step biological process to achieve predictable bone fusion:
- Polarise: The submicron needle-shaped features of the MagnetOs surface polarise circulating immune cells (monocytes) into the pro-healing M2 macrophage phenotype. These cells play a critical role in creating an ideal environment for bone repair by reducing inflammation and promoting healing. 1,2
- Regenerate: M2 macrophages secrete regenerative signalling factors, including osteoactivin and BMP-2. These factors activate mesenchymal stem cells (MSCs) to migrate to the graft site, proliferate, and differentiate into osteoblasts, which lay down new bone. Simultaneously, endothelial cells form capillaries to deliver nutrients and osteogenic cells, further supporting the repair process. 1-5,9-11
- Propagate: In traditional grafts, bone formation starts at the edges and gradually spreads inward. The MagnetOs NeedleGrip™ technology enables bone to grow throughout the entire graft material by directly interacting with circulating osteogenic cells, significantly reducing the risk of non-unions and improving fusion outcomes. †2,3,6
MagnetOs Clinical Evidence
MagnetOs is supported by extensive scientific and clinical studies, including Level I trials. Proven equivalent to autograft in spinal fusion, MagnetOs is used in more than 20 markets worldwide, delivering consistent and predictable outcomes for surgeons and patients.
Interested in MagnetOs?
If you would like more information regarding MagnetOs Contact Us
Interested in the MagnetOs™ Bone Graft: Advancing Orthobiological Innovation ?
Get in touch with our experts today to learn more
Kuros Biosciences is at the forefront of innovation in orthopaedic solutions, dedicated to advancing patient care through groundbreaking scientific research and development. As the inventors of MagnetOs, Kuros Biosciences leverages extensive expertise in osteoimmunology to deliver products that redefine standards in bone graft technology. With a commitment to evidence-based solutions, Kuros continues to set benchmarks in clinical excellence and patient outcomes.
LEDA Orthopaedics is proud to partner with Kuros Biosciences to bring MagnetOs to trauma and orthopaedic clinicians in the UK. With a focus on exceptional service to both the NHS and the independent sector, LEDA supports surgeons and their teams with the tools they need to achieve superior patient outcomes, combining global innovation with local expertise.
†Results from in vivo or in vitro laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com
MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
- Duan, et al. eCM. 2019;37:60-73.
- Van Dijk, et al. eCM. 2021;41:756-73.
- Van Dijk, et al. JOR Spine. 2018;e1039
- Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
- Van Dijk, et al. Clin Spine Surg. 2019;33(6):E276-E287.
- Stempels, et al. Spine. 2024;49(19):1323-1331
- Instructions for Use (IFU) MagnetOs Putty (EU).
- Fusco
- Liguori, et al. Cell Mol Immunol. 2021;18(3):711–722.
- Zhang, et al. Cell Tissue Res. 2017.
- Arosarena, et al. J Cell Physiol. 2011;226(11):2943–2952
Frequently Asked Questions
MagnetOs features NeedleGrip™ surface technology, which enhances bone growth by engaging pro-healing immune cells and promoting stem cell differentiation into bone-forming osteoblasts.
MagnetOs is backed up by an unprecendent and extensive clinical evidence in the field of bone grafts
MagnetOs is highly versatile and can be used in trauma, extremities (foot & ankle, upper limb), hip & knee and pelvic reconstruction, adapting to various surgical needs.
No, MagnetOs is designed for convenient storage at ambient temperatures (max 45ºC), simplifying logistics for surgical teams.
Yes, MagnetOs is free from animal– and human-derived materials, which address ethical considerations for both clinicians and patients.